Pharmaceutical Services / Contract Research Organization (CRO) & Contract Development and Manufacturing Organization (CDMO)
Strategic Profile
Evotec operates in two segments, Shared R&D and Just – Evotec Biologics. The company is executing a strategic portfolio shift toward higher-margin biologics manufacturing and away from lower-margin discovery services. Evotec signed a sale and license agreement with Sandoz on November 4, 2025, transferring the Just - Evotec Biologics Toulouse site and granting an indefinite license to Evotec's continuous biologics manufacturing platform, with key financial terms including approximately US$350m cash for the site, plus upfront license fees and success-based milestones totalling more than US$300m over coming years.
Cyborg Score Rationale
Evotec shows mixed fundamentals with strategic asset repositioning and strong partnerships offsetting execution challenges. Group revenues €535.1m (down 7.1% YoY) with continued softness in early drug discovery (€392.1m, -12.3%). The company faces structural headwinds in discovery services but is benefiting from higher-margin biologics growth and milestone payments from major collaborations.
Top Insights
Just - Evotec Biologics accelerated, with revenues €143.4m, +11.3% and strong non-Sandoz/non-DoD growth.
Evotec announced receipt of a US$5 million milestone payment after the U.S. FDA accepted an Investigational New Drug (IND) application for a collaboration-developed CELMoD™ drug candidate from its strategic protein degradation partnership with Bristol Myers Squibb, which is expected to enter Phase 1 in 2026.
Losses were -196.08 million, 133.7% more than in 2023, reflecting ongoing profitability challenges despite revenue stability.
Evotec has alliance contracts with Bayer, Lilly, Almirall, Chinook Therapeutics, Novo Nordisk A/S, Galapagos NV, Pfizer Inc., Bristol Myers Squibb Company and others.
Named Competitors
Contract Research Organization Services — Leading CRO with preclinical, clinical, and manufacturing services
Integrated Drug Development — Global clinical research and data analytics platform
Biologics Manufacturing — Integrated CDMO with cell/gene therapy and manufacturing capabilities
Clinical Development Services — CRO and contract sales organization services
Recent Developments
(January 2026) Dr. Sarah Fakih appointed as Executive Vice President, Head of Global Communications and Investor Relations
(January 2026) Gates Foundation grant received for AI-optimised affordable biologics advancement through Just - Evotec Biologics
(November 2025) Signed sale and license agreement with Sandoz for Just - Evotec Biologics Toulouse site transfer with €350m+ upfront plus milestone payments
(November 2025) FDA accepted IND application for Bristol Myers Squibb CELMoD™ drug candidate with $5m milestone payment received
Open the full interactive Evotec SE report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.